S100家族蛋白与肾癌关系的研究进展

陈思逸; 来茂德

doi:10.11665/j.issn.1000-5048.20200214

S100家族蛋白与肾癌关系的研究进展

中国药科大学基础医学与临床药学学院

计量
- 文章访问数: 491
- HTML全文浏览量: 1
- PDF下载量: 1129
出版历程
- 刊出日期: 2020-04-24

Expression changes of S100 family proteins and their functional significances in renal cancer

摘要

摘要: 肾细胞癌(renal cell carcinoma，RCC)是常见的泌尿系统恶性肿瘤，全球肾癌发病率为2.2%。S100家族成员众多，在调节细胞内环境钙离子稳态、细胞增殖等一系列重要的生物过程中发挥主要作用。S100家族成员与许多恶性肿瘤的进展密切相关。本文总结了S100在多种肿瘤中的表达及预后关系，并对S100家族各成员在RCC中的表达改变和作用进行详细的综述和分析，为肾癌的研究和诊疗提供了新思路。S100 在肾癌发生过程中VHL/HIF信号通路调控作用的阐释应该是未来的一个重要研究方向。
- S100蛋白 /
- 肾癌 /
- 肾细胞癌 /
- 进展
Abstract: Renal cell carcinoma is a common type malignant tumor of the urinary system. The global incidence of renal cancer is 2. 2%. S100 proteins are involved in the regulations of proliferation, differentiation, apoptosis, and Ca²⁺ homeostasis, etc. S100 proteins are often closely associated with tumor progression. This review lists the expression changes of S100s and their functional significances in renal cancers, providing a new direction for the researches and treatments of renal cancer. The interpretation of S100 in the regulation of VHL/HIF signaling pathways should be a future direction.
- S100 protein /
- renal cancer /
- renal cell carcinoma /
- progress

HTML全文

参考文献(37)

[1]	Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[2]	Donato R,Cannon BR,Sorci G,et al.Functions of S100 proteins[J].Curr Mol Med,2013,13(1):24-57.
[3]	Teratani T,Watanabe T,Kuwahara F,et al.Induced transcriptional expression of calcium-binding protein S100A1 and S100A10 genes in human renal cell carcinoma[J].Cancer Lett,2002,175(1):71-77.
[4]	Liu XH.Expression of S100A1,GLUT-1 and Caveolin-1 in eosinophilic renal cell carcinoma[J].Chin J Pub Health Eng(中国卫生工程学),2017,16(6):754-755.
[5]	Rocca PC,Brunelli M,Gobbo S,et al.Diagnostic utility of S100A1 expression in renal cell neoplasms:an immunohistochemical and quantitative RT-PCR study[J].Mod Pathol,2007,20(7):722-728.
[6]	Ng KL,Morais C,Bernard A,et al.A systematic review and meta-analysis of immunohistochemical biomarkers that differentiate chromophobe renal cell carcinoma from renal oncocytoma[J].J Clin Pathol,2016,69(8):661-671.
[7]	Kuroda N,Kanomata N,Yamaguchi T,et al.Immunohistochemical application of S100A1 in renal oncocytoma,oncocytic papillary renal cell carcinoma,and two variants of chromophobe renal cell carcinoma[J].Med Mol Morphol,2011,44(2):111-115.
[8]	Yang JF,Zhang XY,Qi F.Expression of S100 protein in renal cell carcinoma and its relationship with P53[J].J Centrl S Univ(Med Sci)(中南大学学报医学版),2004,(3):301-304.
[9]	Kato K,Haimoto H,Ariyoshi Y,et al.High levels of S-100a0(alpha alpha)protein in tumor tissues and in sera of patients with renal cell carcinoma[J].JAP J Cancer Res Gann,1985,76(9):856.
[10]	Zhao CF.Expression and function of S100A2 in renal clear cell carcinoma(S100A2在肾透明细胞癌中的表达及功能研究)[D].Chinese PLA General Hospital & Medical School PLA,2016.
[11]	Wang LJ,Matoso A,Sciandra KT,et al.Expression of S100A4 in renal epithelial neoplasms[J].Appl Immunohistochem Mol Morphol,2012,20(1):71-76.
[12]	Yang H,Zhao K,Yu Q,et al.Evaluation of plasma and tissue S100A4 protein and mRNA levels as potential markers of metastasis and prognosis in clear cell renal cell carcinoma[J].J Int Med Res,2012,40(2):475-485.
[13]	Zhou HK, Zhao YB, Zheng SB, et al. Association of S100A4 expression with differentiation and metastasis of renal cell carcinoma [J].J First Mil Meal Univ(第一军医大学学报),2005,(6):712-714.
[14]	Bandiera A,Melloni G,Freschi M,et al.Prognostic factors and analysis of S100a4 protein in resected pulmonary metastases from renal cell carcinoma[J].World J Surg,2009,33(7):1414-1420.
[15]	Lin C,Xin ZQ,Wang WP,et al.Expressions of S100A4 protein and E-cadherin in renal cell carcinoma and their clinical significance[J].J Chin Med Univ(中国医科大学学报),2009,38(1):47-49.
[16]	Lyu XJ, Li HZ, Ma X, et al. Elevated S100A6(Calcyclin)enhances tumorigenesis and suppresses CXCL14-induced apoptosis in clear cell renal cell carcinoma[J].Oncotarget,2015,6(9):6656-6669.
[17]	Lyu X,Li H,Ma X,et al.High-Level S100A6 Promotes metastasis and predicts the outcome of T1-T2 stage in clear cell renal cell carcinoma[J].Cell Biochem Biophys,2015,71(1):279-290.
[18]	Korndörfer IP,Brueckner F,Skerra A.The crystal structure of the human(S100A8/S100A9)2 heterotetramer,calprotectin,illustrates how conformational changes of interacting α-helices can determine specific association of two EF-hand proteins[J].J Mol Biol,2007,370(5):887-898.
[19]	Zhang L,Jiang H,Xu G,et al.iTRAQ-based quantitative proteomic analysis reveals potential early diagnostic markers of clear-cell Renal cell carcinoma[J].Biosci Trend,2016,10(3):210-219.
[20]	Ebbing J,Mathia S,Seibert FS,et al.Urinary calprotectin:a new diagnostic marker in urothelial carcinoma of the bladder[J].World J Urol,2014,32(6):1485-1492.
[21]	Hemmerlein B,Markus A,Wehner M,et al.Expression of acute and late-stage inflammatory antigens,c-fms,CSF-1,and human monocytic serine esterase 1,in tumor-associated macrophages of renal cell carcinomas[J].Cancer Immunol Immunother Cii,2000,49(9):485.
[22]	Zhang L,Jiang H,Xu G,et al.Proteins S100A8 and S100A9 are potential biomarkers for renal cell carcinoma in the early stages:results from a proteomic study integrated with bioinformatics analysis[J].Mol Med Rep,2015,11(6):4093-4100.
[23]	Mirza Z,Schulten HJ,Farsi HM,et al.Molecular interaction of a kinase inhibitor midostaurin with anticancer drug targets,S100A8 and EGFR:transcriptional profiling and molecular docking study for kidney cancer therapeutics[J].PLoS One,2015,10(3):e119765.
[24]	Mirza Z,Schulten H,Farsi HM,et al.Impact of S100A8 expression on kidney cancer progression and molecular docking studies for kidney cancer therapeutics[J].Anticancer Res,2014,34(4):1873.
[25]	Kwon M,MacLeod TJ,Zhang Y,et al.S100A10,annexin A2,and annexin A2 heterotetramer as candidate plasminogen receptors[J].Front Biosci,2005,10:300-325.
[26]	Domoto T,Miyama Y,Suzuki H,et al.Evaluation of S100A10,annexin II and B-FABP expression as markers for renal cell carcinoma[J].Cancer Sci,2007,98(1):77-82.
[27]	Na CH,Hong JH,Kim WS,et al.Identification of protein markers specific for papillary renal cell carcinoma using imaging mass spectrometry[J].Mol Cells,2015,38(7):624-629.
[28]	Gabril M,Girgis H,Scorilas A,et al.S100A11 is a potential prognostic marker for clear cell renal cell carcinoma[J].Clin Eep Metastas,2016,33(1):63-71.
[29]	Liu L,Miao L,Liu Y,et al.S100A11 regulates renal carcinoma cell proliferation,invasion,and migration via the EGFR/Akt signaling pathway and E-cadherin?偊潝眮氼敩猾?呵??瑲欠楂湩獯????椾??攰琱?愬氼???椹??瑢放稨漵氩椺稵甶洸愸戳‵瀱氶申献?扢敲瘾慛挳椰穝甠洠慅扲?癮攠牎猬異獥?猦産湸楅琷椻湩椠扔?楁湫?灡慹瑡椠敂渼瑩猾?睥楴琠桡?瀮爼支癩椾潎略獵汲祯?略湰瑴物敤慥琠敌摥?浥敬瑳愠獡瑳愠瑷楥捬?爠敡湳愠汮?捰敲汩汬?捳慩牮挠楡湣潴浩慶???洠潤瑥楣潲湥?????慮?浲略汮瑡楬挠散湥瑬牬攠?潡灲散湩?汯慭扡敛汊?瀮格慩猾敃???牥慲渠摍潩浣楲獯敥摮?捩潲湯瑮牭潥汮汴攼搯?琾爬椲愰氱嬶?崼??椹??慢渾挨攲琯??椺??祝?????扛??????扣???????????お????????扄牊?孂??崠??吼敩猾愬牥潴瘠慡?倮??慩氾潓畯獭潡癴慩???婸楰浲慥?味?楯??敯瑦?慅汎???楅???????卯?どち?灥牤漠瑷敩楴湨猠?慢湥摳?潴瑹栠敳牴?剴????汭楯杮慧渠摰獡?楩湥?捴慳渠捷敩牴???浬慥牡歲攠牣獥?浬攠摲楥慮瑡潬爠獣?慬湬搠?灡畲瑣慩瑮楯癭敡?瑊桝攮爼慩瀾敃畡瑲楣捩?瑯慧牥杮敥瑳獩孳?崼??椾??椰漱洴攬搼?倾愳瀵??敢搾??愩挺?唲渲椭瘸′倷愮氼慢捲款祛″伲汝漠洠潎畡捺??穩攠捁栬?剨敯灲畲扡??楥???ち????扈???ち??扨???????????戠牡?嬮??嵩￣?娱栰愰湁朱′??婮栠慲湥杮?公?噡???慣湡摲?桩祯灶潡硳楣慵?獡楲朠湤慩汳楥湡杳?扳敛祊潝渮搼?????楥渠?捣慩渼振敩爾嬬?崰??椬??椾漱洹攱搼椯换椾渺攲猵??椲??金?????戳????托????????S,Liu Y,et al.Expression and significance of S100P in human renal clear cell carcinoma[J].J Clin Urol(临床泌尿外科杂志),2014,29(9):776-779.
[30]	Truong LD, Shen SS. Immunohistochemical diagnosis of renal neoplasms[J].Arch Pathol Lab Med,2011,135(1):92-109.
[31]	Teratani T,Watanabe T,Yamahara K,et al.Restricted expression of calcium-binding protein S100A5 in human kidney[J].Biochem Biophys Res Commun,291(3):627.
[32]	Molina AM,Hutson TE,Nosov D,et al.Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma:crossover of a phase 3 study[J].Eur J Cancer,2018,94:87-94.
[33]	Motzer RJ,Escudier B,McDermott DF,et al.Nivolumab versus everolimus in advanced renal-cell carcinoma[J].N Engl J Med,2015,373(19):1803-1813.
[34]	Motzer RJ,Tannir NM,McDermott DF,et al.Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma[J].N Engl J Med,2018,378(14):1277-1290.
[35]	Rini BI,Plimack ER,Stus V,et al.Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma[J].N Engl J Med,2019,380(12):1116-1127.
[36]	Motzer RJ,Penkov K,Haanen J,et al.Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma[J].N Engl J Med,2019,380(12):1103-1115.
[37]	Rini BI